CN111647081A - 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 - Google Patents
一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 Download PDFInfo
- Publication number
- CN111647081A CN111647081A CN202010350291.2A CN202010350291A CN111647081A CN 111647081 A CN111647081 A CN 111647081A CN 202010350291 A CN202010350291 A CN 202010350291A CN 111647081 A CN111647081 A CN 111647081A
- Authority
- CN
- China
- Prior art keywords
- variable region
- chain variable
- human interleukin
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001933 Interleukin-19 Human genes 0.000 title claims abstract description 47
- 108050009288 Interleukin-19 Proteins 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 101000960946 Homo sapiens Interleukin-19 Proteins 0.000 claims description 39
- 230000003321 amplification Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000012163 sequencing technique Methods 0.000 claims description 13
- 102000050317 human IL19 Human genes 0.000 claims description 12
- 210000004408 hybridoma Anatomy 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 238000013461 design Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 4
- 238000001742 protein purification Methods 0.000 claims description 4
- 210000004988 splenocyte Anatomy 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002887 multiple sequence alignment Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 102100039879 Interleukin-19 Human genes 0.000 description 27
- 238000010586 diagram Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 239000013598 vector Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010350291.2A CN111647081B (zh) | 2020-04-28 | 2020-04-28 | 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010350291.2A CN111647081B (zh) | 2020-04-28 | 2020-04-28 | 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111647081A true CN111647081A (zh) | 2020-09-11 |
CN111647081B CN111647081B (zh) | 2022-06-03 |
Family
ID=72340513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010350291.2A Active CN111647081B (zh) | 2020-04-28 | 2020-04-28 | 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111647081B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116355094A (zh) * | 2023-02-21 | 2023-06-30 | 武汉爱博泰克生物科技有限公司 | 抗小鼠白介素12的单克隆抗体及制备方法 |
WO2023205617A1 (en) * | 2022-04-20 | 2023-10-26 | Eli Lilly And Company | Antibodies and methods targeting interleukin-19 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065396A1 (en) * | 1996-08-30 | 2009-06-03 | Human Genome Sciences, Inc. | Interleukin-19 |
WO2010000721A1 (en) * | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
CN102343089A (zh) * | 2010-08-03 | 2012-02-08 | 张明熙 | 一种治疗乳癌的医药组成物 |
US20120034225A1 (en) * | 2010-08-03 | 2012-02-09 | National Cheng Kung University | Suppressing Bone Loss with Anti-IL-19 Antibody |
-
2020
- 2020-04-28 CN CN202010350291.2A patent/CN111647081B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065396A1 (en) * | 1996-08-30 | 2009-06-03 | Human Genome Sciences, Inc. | Interleukin-19 |
US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
WO2010000721A1 (en) * | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
CN102343089A (zh) * | 2010-08-03 | 2012-02-08 | 张明熙 | 一种治疗乳癌的医药组成物 |
US20120034225A1 (en) * | 2010-08-03 | 2012-02-09 | National Cheng Kung University | Suppressing Bone Loss with Anti-IL-19 Antibody |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023205617A1 (en) * | 2022-04-20 | 2023-10-26 | Eli Lilly And Company | Antibodies and methods targeting interleukin-19 |
CN116355094A (zh) * | 2023-02-21 | 2023-06-30 | 武汉爱博泰克生物科技有限公司 | 抗小鼠白介素12的单克隆抗体及制备方法 |
CN116355094B (zh) * | 2023-02-21 | 2023-10-20 | 武汉爱博泰克生物科技有限公司 | 抗小鼠白介素12的单克隆抗体及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111647081B (zh) | 2022-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113150136B (zh) | 新型冠状病毒n蛋白单克隆抗体的制备 | |
WO2020125120A1 (zh) | 一种抗体文库的构建方法及其应用 | |
CN111647081B (zh) | 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 | |
CN105112375A (zh) | 杂交瘤细胞株zjed0-02、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 | |
CN112111006B (zh) | 抗牛结节性皮肤病病毒的抗体、检测试纸及试剂盒 | |
CN110950960B (zh) | 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法 | |
CN111057148B (zh) | 针对牛血清白蛋白bsa的单域抗体及其衍生蛋白 | |
CN111018985B (zh) | 针对牛血清白蛋白bsa的单域抗体的应用 | |
KR20140118979A (ko) | arm-PCR 및 고속 처리 서열 분석을 이용한 항원 특이적 후천성 면역 반응의 확인 | |
CN105524173B (zh) | 一种针对人源抗体Fc片段的纳米抗体及其应用 | |
CN111647086B (zh) | 一种重组小鼠抗人肌酸激酶单克隆抗体、制备方法和应用 | |
CN114276445A (zh) | 轮状病毒重组蛋白特异性抗体、质粒载体及方法 | |
CN110872354B (zh) | 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 | |
CN111647083B (zh) | 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用 | |
CN108484770B (zh) | 重组大鼠抗小鼠cd4单克隆抗体,制备方法和应用 | |
CN112679607B (zh) | 一种肌钙蛋白i e13单链抗体的制备方法 | |
CN105646712B (zh) | 单克隆抗体及其应用 | |
CN105646713B (zh) | 一种单克隆抗体及其应用 | |
CN117003880B (zh) | 抗硫氰酸荧光素单克隆抗体及其应用 | |
CN114539403B (zh) | 靶向人bcma蛋白的兔重组单克隆抗体及应用 | |
WO2022121899A1 (zh) | 一种特异性结合Strep-Tag II标签的抗体及其应用 | |
CN114773462B (zh) | 用于检测牛crp蛋白的重组单链抗体及其应用 | |
CN113201069B (zh) | mcherry或mEOS纳米抗体及其制备方法和应用 | |
CN112094350B (zh) | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体 | |
CN112094345B (zh) | 可应用于肿瘤细胞捕获的小鼠抗免疫球蛋白关联βCD79b的单克隆抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240402 Address after: 430000 west of 3 / F, 21 / F (zone a), R & D building, No. 666, shendun Fourth Road, Donghu New Technology Development Zone, Wuhan, Hubei (Wuhan area of free trade zone) Patentee after: Wuhan Biyu Biotechnology Co.,Ltd. Country or region after: China Address before: Room 103, Building 1-4, Building C2, Phase 1.2, Guanggu Enterprise Mansion, No. 1 Guanshan Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430000 (178 #) Patentee before: Wuhan baijiekang Biotechnology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |